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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating and painful cancers. 
Pancreatic cancer is often highly resistant to therapy owing to inherent chemoresistance and the 
desmoplastic response that creates a barrier of fibrous tissue preventing transport of 
chemotherapeutics into the tumor. The growth of the tumor in pancreatic cancer often leads to 
invasion of other organs and partial or complete biliary obstruction, inducing intense pain for 
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patients and necessitating tumor resection or repeated stenting. Here, we have developed a delivery 
device to provide enhanced palliative therapy for pancreatic cancer patients by providing high 
concentrations of chemotherapeutic compounds locally at the tumor site. This treatment could 
reduce the need for repeated procedures in advanced PDAC patients to debulk the tumor mass or 
stent the obstructed bile duct. To facilitate clinical translation, we created the device out of 
currently approved materials and drugs. We engineered an implantable poly(lactic-co-glycolic)-
based biodegradable device that is able to linearly release high doses of chemotherapeutic drugs 
for up to 60 days. We created five patient-derived PDAC cell lines and tested their sensitivity to 
approved chemotherapeutic compounds. These in vitro experiments showed that paclitaxel was the 
most effective single agent across all cell lines. We compared the efficacy of systemic and local 
paclitaxel therapy on the patient-derived cell lines in an orthotopic xenograft model in mice 
(PDX). In this model, we found up to a 12-fold increase in suppression of tumor growth by local 
therapy in comparison to systemic administration and reduce retention into off-target organs. 
Herein, we highlight the efficacy of a local therapeutic approach to overcome PDAC 
chemoresistance and reduce the need for repeated interventions and biliary obstruction by 
preventing local tumor growth. Our results underscore the urgent need for an implantable drug-
eluting platform to deliver cytotoxic agents directly within the tumor mass as a novel therapeutic 
strategy for patients with pancreatic cancer.
Keywords
pancreatic cancer; chemoresistance; local delivery; patient-derived xenograft; paclitaxel; 
poly(lactic-co-glycolic acid)
1. Introduction
Pancreatic cancer is one of the most lethal adult cancers, having a 5-year overall survival 
rate less than 6%. At the time of diagnosis, only 20% of patients have localized disease that 
can be successfully treated by surgical resection. The vast majority of PDAC patients have 
locally advanced disease, which limits the therapeutic options to radiation and systemic 
chemotherapies. By invading the surrounding vital organs, locally advanced tumors cause 
excruciating symptoms in patients including intense abdominal pain, anorexia, nausea, 
vomiting and jaundice. A major source of suffering for pancreatic cancer patients is the 
development of biliary obstruction due to the growth of the tumor into the biliary duct. This 
obstruction often requires repeated procedures to clear the duct through resection or stenting.
An additional issue with treatment of pancreatic cancer is the development of 
chemotherapeutic resistance. Pancreatic cancer is often highly resistant to chemotherapy due 
to intrinsic cellular chemoresistance, hypovascularity [1-4] and an extensive desmoplastic 
reaction that creates a barrier of fibrous tissue preventing drug transport into the tumor [5, 6] 
(Fig. 1A). Many mechanisms of intrinsic cellular chemoresistance have been reported, but a 
common theme has been linked to the process of epithelial-mesenchymal transition (EMT). 
Several studies have shown that in many solid tumors EMT is correlated with 
chemoresistance, tumor aggressiveness and worsened survival [7-11]. These extrinsic and 
intrinsic chemoresistance mechanisms can synergize and dramatically attenuate the efficacy 
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of systemically administered drugs, resulting in the poor efficacy of systemic chemotherapy 
often observed in PDAC patients. There is growing evidence that overcoming such drug 
delivery barriers can sensitize PDAC cancer cells to conventional chemotherapies, producing 
a beneficial impact on patient outcomes [1-3, 12]. Therefore, we hypothesized that a 
localized delivery approach would provide a new therapeutic option for palliative care of 
pancreatic cancer patients to enhance chemotherapy efficacy and reduce the intense suffering 
associated with their disease.
By integrating established biomaterial-science knowledge, cutting-edge technologies, 
computational modeling and patient-relevant cancer biology models, we engineered an 
implantable device that can safely deliver high concentrations of drugs inside the tumor 
mass to effectively inhibit tumor progression and control its dissemination in nearby vital 
organs. Our overall goal was to create a local delivery system for PDAC patients that could 
be rapidly translated into clinical practice. Consequently, we restricted our studies to FDA-
approved drugs and biomaterial release systems. Poly(lactic-co-glycolic) (PLGA) is one of 
the most safe and well-characterized drug-eluting polymers and can be specifically modified 
to produce tunable local delivery platform for clinical application in pancreatic cancer 
settings. We first created several new patient-derived PDAC cell lines and tested their 
sensitivity to approved chemotherapeutic agents. After finding the cell lines were most 
sensitive to paclitaxel, we used a computational model to predict drug concentrations for the 
compound under different release scenarios. A final formulation for the paclitaxel-eluting 
device (PED) was obtained and we tested the efficacy of the local therapy in two orthotopic 
patient-derived pancreatic xenograft (PDX) mouse models with a comparison to systemic 
therapy. Local therapy was superior in inhibiting tumor growth and local dissemination of 
the cancer cells while reducing accumulation of paclitaxel in other healthy organs, like the 
liver. Moreover, only local delivery of the compound was able to overcome the 
chemoresistance and induce large areas of necrosis within the tumor mass.
Overall, we have developed a drug-eluting device that was highly effective in treating human 
tumors in mice by providing increased drug concentrations inside the neoplastic lesions. The 
device composition provides a generalizable platform consisting of clinically approved 
materials that can deliver local chemotherapy to PDAC patients based on the 
chemosensitivity of their cancer.
This drug-eluting platform has broad implications in many solid tumors with the potential to 
redefine new therapeutic paradigms to treat patients with cancer. By enhancing the effect of 
existing chemotherapeutic agents or releasing compounds that are not currently deliverable 
with systemic administration, our local delivery approach has the ability to improve the 
quality of life and revolutionize patient outcomes by potentially converting locally advanced 
inoperable tumors into resectable lesions.
2. Materials and Methods
2.1 Generation of patient-derived pancreatic ductal adenocarcinoma cell lines
All cell lines were generated from patients using an IRB-approved protocol 2011P001236 at 
the Massachusetts General Hospital. All patients signed consent for discarded tissue use for 
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cell lines before the paracentesis procedure. One liter of discarded ascites fluid was collected 
from each patient and processed accordingly (See Supplementary Materials). We confirmed 
the presence of a pure population of cancer cells after this selection method by sequencing 
for the KRAS mutation (codon 12 and 61) in the remaining cells (See Supplementary 
Materials and Fig. S1A). Using this culture selection method we were able to establish five 
PDAC cell lines from different metastatic PDAC patients. These cell lines are referred to as 
PDAC-1, PDAC-2, PDAC-3, PDAC-5, and PDAC-6. The cell lines were characterized for 
proliferation and drug sensitivity in vitro as well as histology and orthotopic xenografts in 
vivo (See Supplementary Materials).
2.2 Bioinformatics analysis of RNA sequencing data
The initial quality control of the data was carried out using the tool FASTQC. Once it was 
determined that the samples were good, the alignment of the samples to the reference 
genome was carried out using STAR aligner. The duplicate reads were marked using 
PICARD and removed using SAMTOOLS. The resulting BAM files were used to quantify 
the read counts per gene using Htseq-count program. The downstream analysis was carried 
out in R statistical programming language. In order to get an insight into the data, we 
selected 100, 500, 1000 and 2000 most variant genes and did a hierarchical clustering for all 
samples based on the expression for these genes. The data was divided into replicates that 
needed to be compared for specific conditions in this case PDAC 2 and 3 clustered as one 
and PDAC-1, -5 and 6 as another. We used the DESEQ2 package in R for the differential 
expression analysis between the two clusters and to finally get a list of differentially 
expressed genes between any two conditions of interest. The heatmaps were plotted using 
the heatmap.2 function in gplots package in R.
2.3 RNA in situ Hybridization (RNA-ISH
Paraffin-embedded tissue blocks from tumor xenografts were freshly cut and frozen at 
-80°C, then processed as described in the Supplementary Materials accordingly to the 
Affymetrix QuantiGene ViewRNA ISH Tissue-2 Plex Assay.
2.4 Mathematical model of drug distribution
Time invariant rectangular tumor geometry was assumed and partitioned into three 
compartments, the interstitium (denoted by subscript “i”), which is assumed to be fully 
connected, the intracellular space (denoted by subscript “c”) and the microvascular space 
(denoted by subscript “mv”). In modeling local delivery, drug efflux from the device was 
applied as a flux boundary condition and drug transport was calculated in the entire tissue 
domain. By contrast, in intravenous drug delivery each capillary within the tumor acts as a 
time dependent drug source, posing an intractable computational challenge. Thus, drug 
distribution gradients arising from intravenous delivery were only modeled in the vicinity of 
a single capillary. As a result, some of the equations take on slightly different forms based 
on the mode of drug delivery. See Supplementary Materials for a detailed description of 
equations and parameters.
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2.5 Coating of stainless steel substratum with polymeric drug-embedding matrix
We used stainless steel discs (6-mm diameter) with a 1-mm hole to allow suturing during 
implantation. The discs were subjected to ultrasonic cleaning in ethanol and acetone in 
sequence for 15 min. Two different PLGA/paclitaxel formulations were obtained, 
PED_10_200 and PED_20_400, that contained 10% or 20% of polymer and 200μg or 400μg 
of the drug, respectively. See Supplementary Materials for detailed description.
2.6 In vitro drug release kinetics
In vitro release kinetics of Oregon Green (Life Technologies) dye-labeled paclitaxel from 
PED_10_200 and PED_20_400 was evaluated. A sample of each formulation was immersed 
in PBS and placed on a bench top orbital shaker (Thermo Scientific, Model MaxQ™ 4450) 
operating at 40 rpm and incubated at 37°C. At scheduled time intervals, a sample of 50 μl 
was collected and replaced by fresh PBS. Collected media was analyzed by 
spectrofluorimetric assay, the emission of the fluorescent label, after excitation at 488 nm, 
was measured at 503 nm. The linearity of the response was verified over the concentration 
range 0.5 – 250.0 μg/mL (r2 > 0.99). Experiments were run in triplicate on three different 
batches of the synthesized polymer. Results are expressed as percentage of fluorescently-
labeled paclitaxel released over time ± standard deviation.
2.7 Orthotopic xenograft mouse model, tumor burden and overall survival assessment
All animal experiments were approved by the IACUC of Massachusetts General Hospital. 
NOD scid gamma (NGS; NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz) mice were used for the 
orthotopic xenograft model. All mice were female and used between the ages of 4-6 weeks. 
The mice were anesthetized during the procedures (2.5% isoflurane gas). An oblique 2 cm 
incision (skin and peritoneal membrane) from the center of the abdomen up to the inferior 
left ribs was performed. 50 μl of Matrigel and DMEM (1:1) containing 100,000 cancer cells 
was injected into the pancreas. After injection, the abdominal cavity and skin incisions were 
separately closed using absorbable sutures. After two weeks for PDAC-3 and 4 weeks for 
PDAC-6 injected mice, the mice were divided into two groups based upon their tumor 
burden and delivery device was surgically implanted. Drug-delivery devices were sterilized 
in biosafety cabinet under UV light overnight. An oblique 2 cm incision (skin and peritoneal 
membrane) on top of the previous scar was performed. Tumor xenografts were identified 
and PED was sutured onto the tumor surface with a 4-0 absorbable suture. After delivery 
device implantation, abdominal cavity and skin were separately closed with two running 
absorbable sutures. For intravenous administration of paclitaxel, the drug was dissolved in 
100% ethanol to a final concentration of 25 mg/mL. Prior to tail vein injection, 40 μl of a 
paclitaxel stock solution was mixed with 40 μl of Cremophor EL (1:1) and then diluted 20.8 
times in a saline solution to produce a final paclitaxel concentration of 0.6 mg/ml. Mice 
were placed in a dedicated tail vein injection cabinet and a 1 ml syringe with 30G needle 
was used to inject 170 μl of the paclitaxel solution weekly (100 μg/week) to each mouse. 
Mouse tumors were monitored using in vivo luciferase imaging on the IVIS Lumina 
platform (Perkin Elmer/Caliper). Four weeks after PED implant the mice were given an 
intraperitoneal injection with 150 μl luciferin, euthanized and IVIS imaging performed for 
the primary tumors, peritoneal dissemination, liver and lungs. The organs were then 
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harvested and stored for histological analysis. See Supplementary Materials for more details 
of the methods used. Necroscopy ended by assessing tumor size and weight. In the survival 
experiment 12 NOD-SCID gamma mice were injected with 700000 PDAC-3 cells. After 10 
days from injection, mice were randomized into two groups with homogenous tumor burden, 
and 5 mice were re-operated to surgically implant the PED. In parallel, mice in the control 
group were treated with intravenous weekly doses of paclitaxel (100 μg/week) for four 
consecutive weeks. Mice were sacrificed when they met the end stage criteria of our 
approved mouse protocol.
2.8 In vivo fluorescent drug distribution
Devices with the PED_20_400 formulation were created using Oregon Green dye-labeled 
paclitaxel. Devices were implanted in the NSG mice in direct contact with the tumor mass 
four weeks following cell injection. The control group consisted of weekly administration of 
fluorescent paclitaxel via tail vein injection. After two weeks of treatment, animals were 
sacrificed, the pancreas removed and the tissue was snap frozen in liquid nitrogen and 
embedded for cryosectioning. Sectioning was performed in the direction perpendicular to 
the delivery device placement, in order to visualize the depth of drug penetration. Slides 
were then washed and mounted with media containing propidium iodide to stain the nuclei. 
Confocal imaging was performed in the green (drug) and red (nuclei) channels using a Zeiss 
LSM 510 (Confocal Core Facility at the Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA) and Nikon A1R Ultra-Fast Spectral Scanning Confocal 
Microscope (Koch Institute Swanson Biotechnology Center, Cambridge, MA). Multiple 
images were taken to create z-stacked images and reconstructed using the microscope 
software (Zeiss). The software was used to determine the green intensity profiles along a 
selected line in order to analyze depth of drug penetration.
3. Results
3.1 Intrinsic and extrinsic factors that determine PDAC chemoresistance
To design a local therapy relevant to human pancreatic cancer, we generated five patient-
derived cell lines by culturing the ascites fluid from patients with metastatic pancreatic 
cancer. The cancer origin was confirmed by KRAS gene mutation sequencing matched to 
the initial diagnostic biopsy (see SI Appendix and Fig. S1A). These newly established 
PDAC lines were orthotopically injected into immunodeficient mice to demonstrate 
tumorigenicity of all cell lines (Fig. S1B). Histological analysis of the tumor xenograft 
revealed a spectrum of high grade, undifferentiated morphology in PDAC tumors generated 
from lines PDAC-2 and PDAC-3, while tumors from PDAC-1 and PDAC-6 exhibited a 
differentiated morphology with gland-forming ability and notable stromal deposition. 
PDAC-5 was in the middle of this spectrum and showed an intermediate grade tumor and 
PDAC-6 produced the highest desmoplastic stromal reaction (Fig. 1B). Thus, these lines 
provided a range of pancreatic cancer properties, representing the heterogeneity inherent in 
patient disease.
To better characterize the different phenotypes observed from these cell lines, RNA-
sequencing was performed on the tumor lines. Unsupervised clustering of gene expression 
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profiles recapitulated the similarities among cell lines previously categorized by their 
histological differences (Fig. 1C). Differential expression analysis of the two groups of cell 
lines revealed increased expression of mesenchymal genes in PDAC-2 and PDAC-3 when 
compared to PDAC-1, PDAC-5, and PDAC-6 (Fig. S1C). We then applied a 62 gene set [13] 
previously shown to separate PDAC tumors and cell lines into three different subtypes 
including exocrine-like, classical, and quasi-mesenchymal. Consistent with our global 
RNAseq analysis, we found that PDAC-1, PDAC-5 and PDAC-6 to have a classical 
epithelial phenotype while PDAC-2 and PDAC-3 had a quasi-mesenchymal expression 
signature (Fig. 1D). These differences in classical epithelial and quasi-mesenchymal gene 
expression signatures were maintained in vivo as seen in patient-derived xenograft (PDX) 
tumor stained for epithelial and mesenchymal markers [14] with RNA in situ hybridization 
(Fig. 1E).
Paralleling the differences in transcriptional signatures, PDAC-2 and PDAC-3 had faster 
proliferation rates and higher migration through trans-well chambers compared to the more 
well-differentiated PDAC lines, PDAC-1 and PDAC-6 (Fig. 1F, see Supplementary Materials 
and Fig. S1E). To further characterize differences in key EMT markers at the protein level, 
we performed a western blot assay of the classic epithelial marker E-cadherin (CDH1) and 
mesenchymal marker Vimentin (VIM) (Fig. S1F). Notably, we found that PDAC-3 is the 
only pancreatic line that has significant loss of E-cadherin and acquisition of Vimentin at the 
protein level. This indicates that even though PDAC-2 and PDAC-3 share many quasi-
mesenchymal features, E-cadherin and Vimentin protein status are significantly different.
We then tested the intrinsic drug resistance of our patient-derived cell lines to known active 
chemotherapeutic agents in pancreatic cancer treatment (Fig. 1G, Supplementary Materials 
and Fig. S1G). All cell lines showed significant chemoresistance to single agent 5-
fluorouracil, oxaliplatin, and irinotecan. There was striking single agent activity of 
gemcitabine and paclitaxel at nanomolar (nM) concentrations in PDAC-1, PDAC-2, and 
PDAC-6 (Fig. 1H and Supplementary Materials). The PDAC-5 cell line had intermediate 
sensitivity to these agents, but notably, PDAC-3 had significantly increased multi-drug 
resistance compared to the other patient derived cell lines. Given the differences in PDAC-2 
and PDAC-3 sensitivity to chemotherapy despite shared quasi-mesenchymal features, we 
hypothesized that the differences in EMT proteins confer intrinsic chemoresistance not 
found in RNA-seq data. Indeed, the western blot of of the classic epithelial marker E-
cadherin (CDH1) and mesenchymal marker Vimentin (VIM) revealed PDAC-3 had much 
lower E-cadherin and higher Vimentin compared to all other cell lines including PDAC-2. 
Interestingly, PDAC-5 also had diminished E-cadherin levels, albeit not as much as PDAC-3, 
and was also found to be the second most resistant cell line to paclitaxel. This is consistent 
with previous work indicating that quasi-mesenchymal cell lines are generally more 
chemoresistant [13]. Together, this suggests that EMT marker protein status may be a better 
predictor of chemosensitivity than the other characteristics.
Interestingly, paclitaxel had the most activity across all cell lines, including PDAC-3, 
outperforming even gemcitabine, the only single agent with demonstrated efficacy in 
humans (Fig. 1H). The combination of paclitaxel efficacy across these cell lines and the 
known difficulty in delivering this compound systemically, supported the merit of 
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developing a paclitaxel localized therapy platform for PDAC. We selected the PDAC-3 cell 
line for its intrinsic chemoresistant behavior and PDAC-6 for its robust stromal reaction to 
cover the spectrum of PDAC extrinsic and intrinsic chemoresistance in our in vivo 
experimental models.
3.2 Systemic chemotherapy fails to deliver the agents to the tumor core
We developed a computational model to examine the role of transport barriers in resistance 
to chemotherapy by predicting the spatiotemporal dynamics of paclitaxel distribution in 
PDAC-3 tumor tissue after intravenous (I.V.) administration of chemotherapy. The focus on 
paclitaxel distribution was dictated by its enhanced efficacy against all cell lines tested and 
the steepest dose response curve. A compilation of computational modeling transport 
parameters is provided in Supplementary Materials Tab. S1 and S2. Model simulations 
predict that intravenous delivery of paclitaxel provides limited spatial distribution over time 
(Fig. 2A, Supplementary Materials Movie S1), with a peak drug concentration of 12 μM and 
a rapid decay from the blood capillaries (Fig. 2B), reinforcing the assertion that standard-of-
care systemic treatment fails to deliver the drug at significant concentrations within the 
tumor. This indicates that the IC50 of intravenous paclitaxel would only be reached in the 
region immediately surrounding the tumor vasculature. To verify the in vivo relevance of 
these computational predictions, we quantified the distribution of fluorescently-labeled 
paclitaxel inside PDAC-3 orthotopic patient-derived xenograft two hours post intravenous 
administration [15]. Consistent with matching model predictions, confocal images of tissue 
sections showed localized patterns of fluorescently-labeled drug that sparse the 
microvasculature (Fig. 2C). Quantitative image analysis confirmed that paclitaxel merely 
penetrated up to 10 μm from the vascular source (Fig. 2D). Linear scan analysis revealed 
only a very limited amount of the drug actually present in the tissue (Fig. 2E). These results 
demonstrate the predictive power of the computational model and highlight the major 
limitations of delivering paclitaxel intravenously due to the tumors desmoplastic effects and 
hypovascularity.
3.3 Design of an implantable drug delivery platform for local therapy
To overcome the systemic delivery barrier introduced by fibrosis surrounding the tumor and 
lack of vasculature, we developed a biodegradable polymer based drug-eluting device for 
localized delivery of chemotherapeutic agents. We tested this device in comparison to 
intravenous therapy using a patient-derived xenograft mouse model (Fig. 3A). Guided by our 
computational model and considerations required for surgical implantation, we designed a 
mouse-size paclitaxel eluting device (PED) as a poly(lactic-co-glycolic) acid (PLGA) matrix 
embedded with paclitaxel adhered onto a 316L stainless steel disc. This setting allowed us to 
accurately investigate polymer-metal interface, adhesion, degradation and release kinetics. 
We tested two different formulations, PED_10_200 and PED_20_400, differing from one 
another by PLGA concentration and paclitaxel amount. Both systems were fully 
characterized (see Supplementary Materials and Fig. S2A), and surface chemical analysis 
confirmed the presence of polymeric atomic elements at the expected stoichiometric ratio 
(see Supplementary Materials and Fig. S2B-C). Morphological examination of both 
formulations revealed a smooth surface without cracks or bubbles (Fig. 3B) and a uniform 
thickness across all measured locations as determined by environmental scanning electron 
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microscopy (Fig. 3C). Polymer thickness is highly important due to its direct relationship to 
the PLGA degradation kinetics, and therefore to the elution rate of paclitaxel. The hydrolytic 
bulk degradation of the polymer requires the surrounding fluids to imbibe the coating layer, 
triggering bulk degradation [16] and initiating drug release without generating dangerous 
superficial cracks that can be seen in other polymer systems. In vitro incubation in aqueous 
media allowed us to verify significant adherence to the metallic substratum and homogenous 
degradation, as shown by the presence of a hydrated coating at later time points (Fig. 3D).
The PLGA-based drug release formulations are dependent on polymer degradation, and 
affected by shape, polymer, drug ratio, and the mechanism of hydrolysis [17-19]. We 
achieved sustained release of fluorescently-labeled paclitaxel for more than one month from 
both PED_10_200 and PED_20_400 devices. We successfully created a platform technology 
where the release kinetics can be accurately tuned using different ratios of PLGA and 
paclitaxel. Furthermore, the two delivery devices are designed to release different amounts 
of chemotherapeutic agent with similar kinetics (Fig. S2D). By doubling both the drug 
content and polymer concentration, we were able to tune the formulations to accomplish a 
linear release of paclitaxel, which boosted the effective dose and increased the length of in 
vitro release from 45 days (PED_10_200) to 60 days (PED_20_400) (Fig. 3E). An 
additional consideration is that the inflammation at the site of implantation following 
stenting or any other procedure is very common and the release of a chemotherapeutic drug 
too early may result in harmful complications by preventing healing. To address this issue, 
we modified the polymer concentration engineering a delay in drug release between 10 to 17 
days, allowing time for the surgical wounds to heal before chemotherapy began.
3.4 Local therapy enhances intratumoral drug distribution
The rationale behind our strategy was to demonstrate that local therapy would allow for 
higher intratumoral paclitaxel distribution and cytotoxicity compared to intravenous 
administration. Computational modeling predicted that the release kinetics achieved by the 
PED_20_400 device (Supplementary Materials and Fig. S2E) should provide markedly 
improved intratumoral paclitaxel distribution with increased drug concentration by day 3, 
and extend over a prolonged period of time to reach tissue concentrations as high as 45 μM 
(Fig. 4A, Supplementary Materials Movie S2). Moreover, linear plots forecasted a depth of 
penetration as high as 1,000 μm after 30 days of treatment (Fig. 4B).
To evaluate the computational prediction of significantly higher delivery of paclitaxel deep 
into the tumor core at cytotoxic concentrations, we recapitulated the experiment in mice 
bearing delivery devices with fluorescently-labeled paclitaxel to measure drug distribution 
inside PDAC-3 pancreatic PDX tumors. Two weeks after implantation, the tumors 
demonstrated deposition of fluorescent paclitaxel when observed under a dissecting 
microscope (Fig. 4C). To quantify intratumoral drug penetration, serial sections were taken 
from the tumor perpendicular to the delivery device and were imaged using confocal 
microscopy (see Supplementary Materials and Fig. S2F). The paclitaxel distribution in the 
local delivery device group had markedly increased drug concentration within the tumor in 
comparison to intravenous dosing (Fig. 4D and Fig. 2C). The local drug delivery achieved a 
qualitatively different distribution pattern with high drug deposition spanning over 140 μm 
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of the surface at the tumor/device interface (Fig. 4E-F). Paclitaxel penetration depth 
extended over 400 μm from the delivery device, in perfect accordance with the prediction of 
the computational model at 14 days, a result that was 40-fold deeper than what was achieved 
with intravenous administration (Fig. 4F versus intravenous concentration shown in Fig. 2E). 
Together, these results demonstrate that local delivery of high payloads of anti-neoplastic 
agents can overcome the transport barriers that impede adequate distribution following 
systemic administration (Supplementary Materials and Fig. S2G-H).
We took advantage of fluorescently-labeled paclitaxel to also detect drug distribution inside 
mouse organs and within tumor xenografts. We demonstrated that drug is differentially 
distributed between primary tumors and mouse organs in systemic versus localized treatment 
(Fig. S2I). Specifically, in mice-bearing PED, paclitaxel retention inside the xenografts 
tumors is significant higher (6.5 times) compared to distal organs (5.2 ± 0.1 fluorescent 
signal/millisecond in tumor xenografts vs. 0.8 ± 0.4 fluorescent signal/millisecond in distal 
organs). This highlighted the modest exchange of paclitaxel between pancreatic tumors and 
mouse circulation. These data are in accord with the potential of reducing the high systemic 
side effects and organ toxicity present with many chemotherapy treatments. Moreover, 
tumor xenografts in IV mouse group have 3.9 times lower concentrations of paclitaxel 
compared to PED-treated tumors (1.3 ± 0.5 fluorescent signal/millisecond in IV treated mice 
vs. 5.2 ± 0.1 fluorescent signal/millisecond in PED-treated mice). All together, these results 
are indicative of minimal systemic distribution of paclitaxel when locally delivered from 
PED, which can potentially limit the systemic side effects of compounds in PDAC patients.
3.5 Local therapy has enhanced efficacy for treatment of pancreatic tumor xenografts
To test efficacy of our local approach, mice were injected with luciferase-expressing 
pancreatic cancer lines to create orthotopic tumors. We investigated the PDAC-3 cell line as 
a model of intrinsic chemoresistant behavior and the PDAC-6 cell line as a model of 
extrinsic chemoresistance through development of a desmoplastic stromal barrier. After 2 or 
4 weeks following the injection with PDAC-3 or PDAC-6 cells, the mice were randomized 
into two treatment groups with systemic therapy or local delivery of paclitaxel (Fig. S3A). 
The design of the local delivery device allowed for direct surgical implantation and fixation 
to the tumor using standard surgical sutures to avoid any issues of device migration or off 
target delivery. The control group was treated with equivalent total dose of paclitaxel 
through intravenous injection given weekly for 4 weeks (Fig. 5A). Safety of the device was 
determined by weekly examinations of mice bearing the local delivery device. All mice 
survived surgical implantation, and none showed any detectable postoperative 
complications.
In vivo efficacy was assessed by comparing the tumor burden with the local delivery device 
versus mice treated with an intravenous injection of paclitaxel. Tumor burden was assessed 
by bioluminescence imaging during treatment, and by measuring ex vivo the pancreatic 
tumor volumes and mass. Both PDAC-3 and PDAC-6 PDX tumors responded significantly 
more to local delivery of paclitaxel compared to the systemic regimen. After a month of 
treatment, we observed a 12-fold and 2-fold average reduction of viable tumor volume by in 
vivo luciferase imaging in respective PDAC-3 and PDAC-6 tumors in mice with the local 
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delivery device compared to mice treated with intravenous paclitaxel (Fig. 5B-C). 
Furthermore, mice treated with the local delivery device presented both lower pancreatic 
tumor mass and volume (Fig. 5D-F, Supplementary Materials and Fig. S3B) compared to 
control mice. Necropsy examinations macroscopically confirmed the absence of any injuries 
to abdominal organs surrounding the local delivery device and the absence of device 
displacement within the peritoneal cavity (Supplementary Materials and Fig. S3C). 
Histological analysis of the xenograft tumors showed preserved tumor architecture in 
animals exposed to intravenous paclitaxel, while massive areas of necrosis were seen in 
tumors treated with the PED (Fig. 5G). Systemic toxicity of PED was ruled out by carefully 
assessing organ integrity during mouse autopsy, and by reviewing with a pathologist blinded 
to specimen treatment hematoxylin and eosin tissue slides obtained from muscle, lung, liver, 
ovary, kidney and spleen of mice-bearing PED to confirm a normal organ architecture (Fig. 
5H).
These results combined with our viable tumor assessment by luciferase-based imaging 
indicate that the measurable effects of localized therapy are greater than the reduction in 
total tumor size alone given the substantial contribution of necrotic non-viable cells in the 
tumor mass. Moreover, we found better control of local tumor dissemination in mice-bearing 
PDAC-6 tumors treated with the local delivery device compared to mice treated with 
equivalent doses of intravenous paclitaxel (Fig. 5I; Supplementary Materials).
To test whether the higher response to treatment of the localized delivery approach would 
have a favorable impact on overall survival, we performed an additional in vivo experiment 
using PDAC-3 line. We observed a 28-day increase in the median overall survival of mice 
treated with PED compared to mice treated with a systemic regimen of paclitaxel (Fig. 5J, 
p=0.0015), increasing life expectancy in our model.
Altogether, our results demonstrate the ability to control pancreatic cancer progression in 
terms of tumor growth, local dissemination, and survival when a local delivery approach is 
used over a traditional systemic delivery.
4. Discussion
Over the last 40 years, systemic chemotherapies have been shown to be largely ineffective in 
pancreatic cancer. A plethora of strategies have been implemented for improving drug 
delivery – including, liposome formulations [20] and proteins as natural biomaterials to 
stabilize drug deliverability [21]. These studies showed some promising results although 
they still rely on systemic delivery and its limitation. Using a biodegradable PLGA polymer, 
we developed a highly tunable multi-purpose drug-eluting device to deliver elevated 
payloads of chemotherapeutic agents that can be locally released to reach higher 
intratumoral concentrations not achievable by systemic administration. By means of 
fluorescently-labeled paclitaxel, we demonstrated significantly increased tissue penetration 
of drug using the local delivery device compared to systemic intravenous dosing. The choice 
of the optimal material for drug delivery formulations is dictated by the simultaneous 
presence of the following characteristics: i. Homogenous mixture of polymer and drug, to 
ensure spatial control of drug release; ii. Inert polymer-solvent-drug interactions, to protect 
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pharmacological activity; and iii. Compatibility of matrix preparation methods with 
manufacturing techniques for successful translation into the clinic.
To enhance clinical translation, our choice of materials and drugs was restricted to FDA-
approved compounds. In prior work, another group had created a pancreatobiliary drug 
eluting stent using a polyurethane material that was shown to be safe for humans [22-24]. 
However, the efficacy was not achieved, potentially due to limited transport of the drug to 
the primary tumor from the biliary system and the lack of controlled polymer erosion to 
obtain adequate sustained drug release. Our approach of creating a device that can be used to 
wrap the tumor/biliary duct has the advantage of allowing greater material delivery, 
removing exposure the biliary flow that may cause drug washout and facilitating patient 
specific delivery of the drug tailored to the individual's tumor burden. The PLGA-coated 
device ensured reliable and predictable in vivo release kinetics that are tailor-designed to 
match the specific anatomical position and requirement of PDAC with release delayed for at 
least 7 days to allow for effective wound healing followed by a sustained constant elution for 
at least two months. In our studies, this continuous delivery of high drug concentration was 
achievable without any adverse effects to the animals and with a notable reduction of viable 
tumor cells of two different PDAC patient-derived xenografts. It's worth to notice, the 
hypovascularity of the tumor mass, major barrier of systemic delivery, ensures high retention 
within the tumor mass in the case of local delivery by hindering the leak of the drug into the 
circulation. Thus we transform one of the bigger limitations of systemic administration in 
pancreatic cancer into a strength for a localized approach.
The results obtained in our study provide proof-of-principle that effective local delivery of 
conventional cytotoxic agent can overcome intrinsic and extrinsic chemoresistance 
mechanisms, opening new therapeutic strategies to improve the outcomes of PDAC patients. 
Notably, similar to our in vitro testing, paclitaxel is efficacious when enhanced systemic 
delivery vehicles are employed [25-27]. The albumin nanoparticle encapsulated paclitaxel 
system (nab-paclitaxel) was shown to be effective in combination with gemcitabine in a 
randomized phase III trial [28], though response rates were only modestly improved to 23% 
versus 7% with a survival benefit of 1.8 months. These effects may be due to improved 
tolerability of nab-paclitaxel or longer half-life in circulation as demonstrated in a mouse 
model [29]. Our results suggest that even greater on-target cytotoxicity can be achieved by 
delivering agents like paclitaxel directly to the tumor resulting in dramatically increasing 
overall median survival of more than 50% following improved response rates and decreased 
side effect profiles. Furthermore, we showed that this platform can help to control local 
tumor invasion, acting as a physical barrier, which would potentially translate to better 
palliation of symptoms related to bile duct occlusion and local invasion into surrounding 
tissues and vital organs.
To successfully propel a local delivery approach from the bench to the clinic, it is important 
to provide the physicians with a flexible drug-eluting platform that can be tuned to the 
PDAC patients. The approach tested in these studies is highly adaptable in its use and 
application. It can be fabricated in virtually any shape with tailorable release kinetics and 
can be easily adapted to several therapeutic strategies (Fig. 6). For instance, the local 
delivery device can be applied to a flexible, rather than metallic, substrate with the 
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polymeric formulation to create a foldable, completely biodegradable, multi-organ drug-
eluting platform (Fig. 6, Drug Delivery Matrix – DDM). A translation of our mouse-size 
drug-eluting device for humans could be implanted during an open or laparoscopic surgical 
procedure directly in contact with the tumor. This may provide a strategy to enhance 
neoadjuvant treatments in unresectable locally advanced tumors with the potential to 
increase the survival of these patients, which currently is less than 12 months [30-32]. 
Another application would be to assemble the PLGA matrix with a rigid tubular plastic/
metal substrate as a novel pancreatobiliary stent-based drug release platform (Fig. 6, Drug 
Releasing Stent – DRS). This would provide both mechanical support for the ductal system 
and release high concentrations of chemotherapy into the compressing tumor. This may lead 
to a significant increase in the longevity of the stent, which would improve our ability to 
palliate biliary obstruction symptoms, reduce the number of re-stenting procedures, and 
improve the quality of life in patients with both pancreatic and bile duct cancers.
5. Conclusions
Overall, the results obtained in our study are a proof-of-principle that local drug delivery 
platform can effectively overcome intrinsic and extrinsic PDAC chemoresistance, opening 
the door for novel strategies to treat patients with pancreatic cancer. By implanting a local 
drug-eluting device, we could improve the survival of patients with locally advanced tumors, 
who currently have a life expectancy of several months, and the quality of life of metastatic 
patients, who suffer from debilitating symptoms caused by local tumor infiltration. All of 
these advantages are relevant to many locally advanced inoperable solid tumors. From an 
initial basis in pancreatic cancer this approach can therefore be expanded to other types of 
cancer like colorectal cancer, and has the potential to resuscitate several drugs that have been 
shelved after clinical trials because of inadmissible systemic toxicity. In conclusions, our 
target delivery platform addresses a clinical problem affecting the majority of cancer patients 
and provides the mechanistic insight to drive this concept to the clinic safely, effectively and 
rapidly.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Intrinsic and extrinsic factors determine PDAC chemoresistance
(A) Schematic of factors involved in PDAC chemorefractory behavior including (i) intrinsic 
mechanisms related to cancer cell biology and (ii) extrinsic reasons due to drug delivery 
barrier. (B) Representative pictures of H&E-stained tumor sections demonstrating different 
degrees of stromal deposition. Well-differentiated (PDAC-1 and -6), poorly differentiated 
(PDAC-2 and -3), and intermediate grade (PDAC-5) tumors are shown (“T” = tumor cells; 
“S” = stromal cells; Bar = 20 μm). (C) Unsupervised hierarchical clustering of one thousand 
most differentially expressed genes among all patient-derived PDAC lines. The heat map 
shows that PDAC-2 and PDAC-3 cluster together while PDAC-1, PDAC-5 and PDAC-6 
cluster separately. (D) Unsupervised hierarchical clustering using an epithelial/mesenchymal 
gene signature (62 genes) to differentiate epithelial (CL) vs. quasi-mesenchymal (QM) and 
exocrine-like (EX) tumor types and cell line behavior. The heat map shows an 
overexpression of epithelial genes (CL) in PDAC-1, PDAC-5 and PDAC-6 while a 
downregulation of those genes in PDAC-2 and PDAC-3. These lines display an up-
regulation of mesenchymal genes (QM). (E) Representative images of epithelial (CDH1, 
EPCAM, KRT5, KRT7, KRT8, KRT18, KRT19; red) and mesenchymal (FN1, CDH2, 
SERPINE1; blue) markers identified by RNA in situ hybridization staining. Epithelial tumor 
cells are denoted by arrowheads, while mesenchymal tumor cells are indicated by arrows 
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(Bar = 20 μm). (F) Cellular migration changes demonstrated by transwell migration assay. 
PDAC-2 and PDAC-3 show a higher migration ability compared to the other PDAC lines. 
Statistically significant difference with *P<0.05, **P<0.01 or ***P<0.001. (G) In vitro 
paclitaxel sensitivity of PDAC cell lines shown by MTT assay. (H) Table with the IC50 of all 
PDAC cell lines against paclitaxel, gemcitabine, fluorouracil (5-FU), oxaliplatin, irinotecan 
(data in E and G are displayed as mean ± standard deviation).
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Figure 2. Computational modeling of drug delivery to pancreatic tumors
(A) Layout of the computational domain consisting of a single vascular capillary (in pink) 
from which intravenous delivered drug (green) is transported into the surrounding tumor 
tissue (red) and distributes via interstitial diffusion/binding and cell uptake/binding. 
Underneath is represented the presence of drug over a time course of 24 hours within the 
tumor mass. (B) Linear representation of tissue distribution predicts that drug will reach 
tumor site at a very limited concentration. (C) Confocal imaging of a tumor tissue section 
after 14 days treatment consisting of weekly injection of paclitaxel-Cremophore 
formulation. Image taken two hours after intravenous injection highlights presence of the 
fluorescent paclitaxel only at the lumen/tissue interface (Bar = 100 μm). (D) Analysis of the 
fluorescence intensity at the surface. (E) Fluorescence intensity are in accordance with 
computational prediction of very limited drug penetration (data shown are displayed as mean 
± standard deviation).
Indolfi et al. Page 18
Biomaterials. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Design and characterization of an implantable paclitaxel eluting device
(A) Schematic of localized therapeutic approach with a paclitaxel eluting device (PED). (B) 
Macroscopic visualizations of the local delivery device (Bar = 3 μm). (C) Evaluation of 
coating thickness using scanning electron microscopy (Bar = 100 μm). Coating methodology 
ensured a platform technology with similar outcomes for two different formulations 
differing in PLGA amount (10% and 20% respectively) and paclitaxel loading (200 μg or 
400 μg respectively; “C” = coating and “S” = steel). (D) Characterization of degradation of 
the coatings. Bulk polymeric degradation was homogeneous and without superficial cracks. 
(E) In vitro linear release kinetics showed tunable delivery for over a month from both 
formulations with adjustable therapeutic dose (data are displayed as mean ± standard 
deviation).
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Figure 4. Localized therapeutic strategy implementing PED greatly enhances intratumoral 
deliverability of chemotherapeutic agents
(A) Schematic of the computational domain consisting of a confined tumor tissue (red), the 
device as source of drug (green) taking into consideration interstitial diffusion/binding, cell 
uptake/binding and capillary clearance. Underneath is represented drug distribution over a 
course of 30 days within the tumor mass. (B) Linear representation of intratumoral drug 
distribution predicts elevated paclitaxel tissue retention as a function of release kinetics and 
extended over 1 mm after 30 days of treatment. (C) Representative fluorescent image under 
a dissecting microscope of tumor mass harvested 14 days post-treatment points out a 
macroscopic drug presence (Bar = 3 μm). (D) Confocal analysis of tumor tissue sections 
highlight the extensive penetration of the drug at increased distance form the tumor/PED 
interface (Bar = 100 μm). Image represents a time point of 14 days post-implant of the PED. 
(E) Surface analysis and (F) Fluorescent intensity from tissue was in accordance with 
computational predictions of drug penetration after 14 days of treatment (data in are 
displayed as mean ± standard deviation).
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Figure 5. Response to treatment is highly improved by targeted delivery of chemotherapy
(A) Schematic representation of the in vivo model design used to compare the efficacy of 
paclitaxel delivered intravenously (intravenous) to the paclitaxel eluting device (PED) 
treatment. (B-C) Relative tumor growth curves of PDAC-3 and PDAC-6 mouse xenografts 
after either paclitaxel intravenous or PED treatment (data are displayed as mean ± s.e.m). 
(D) Representative images of tumor masses isolated from PDAC xenografts after treatment 
with intravenous or locally delivered paclitaxel. (E-F) Tumor volume of PDAC xenografts 
after treatment with intravenous or locally-delivered paclitaxel (data are displayed as mean ± 
standard deviation). (G) Histological analysis of the tumor showing areas of necrosis (N) in 
tumors treated with locally delivered paclitaxel compared to preserved tumor architecture 
(T) in mice treated with intravenous paclitaxel (bar = 100 μm). (H) Representative images of 
different organs of mice treated with PED. The histological tissue sections show intact organ 
architecture without any area of necrosis (hematoxylin and eosin staining, bar = 150 μm). (I) 
Graph showing reduction of the local peritoneal dissemination in PDAC-6 injected mice that 
were treated with local delivery device compared to systemic administrations of paclitaxel. 
*statistically significant difference with p < 0.05. **statistically significant difference with p 
< 0.01. (J) Kaplan-Meier curves showing a significant 28-day increase in the median overall 
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survival of mice treated with PED compared to mice treated with paclitaxel I.V. (** 
p=0.0015).
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Figure 6. Schematic layout of different types of device and approach
Fully biodegradable Drug Delivery Matrix (DDM) inserted via minimal invasive 
laparoscopic surgery cages the tumor, controlling invasion in nearby organs, and locally 
releases the agent increasing efficacy of treatment. Drug Releasing Stent (DRS) implanted 
through ECR relieves blockage of the bile duct and locally releases the agent increasing 
efficacy of treatment.
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